Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Shares Issued (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Shares Issued for 6 consecutive years, with $73000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Shares Issued fell 99.94% to $73000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $157.9 million, a 0.23% change, with the full-year FY2025 number at $264000.0, down 99.83% from a year prior.
  • Shares Issued was $73000.0 for Q4 2025 at TScan Therapeutics, down from $125.1 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $125.1 million in Q4 2024 to a low of $5000.0 in Q3 2022.
  • A 5-year average of $22.9 million and a median of $108000.0 in 2021 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: surged 8947600.0% in 2021, then tumbled 99.99% in 2022.
  • TScan Therapeutics' Shares Issued stood at $89.5 million in 2021, then tumbled by 99.92% to $69000.0 in 2022, then skyrocketed by 71955.07% to $49.7 million in 2023, then soared by 151.7% to $125.1 million in 2024, then crashed by 99.94% to $73000.0 in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Shares Issued are $73000.0 (Q4 2025), $125.1 million (Q4 2024), and $32.7 million (Q3 2024).